The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Atezolizumab Immunotherapy: Anti-PD-L1 Monoclonal Antibody

Use in lung, urothelial, breast and hepatocellular cancers

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Onkoloji department. Book Appointment →

What is Atezolizumab Immunotherapy: Anti-PD-L1 Monoclonal Antibody?

Atezolizumab binds PD-L1 on tumor and immune cells and prevents it from inhibiting T cells through PD-1 and CD80.

The antibody is Fc-engineered to limit antibody-dependent cellular cytotoxicity and preserve activated T cells.

It is administered intravenously as 1200 mg every 3 weeks or 1680 mg every 4 weeks.

Key approvals include first-line metastatic NSCLC (with chemotherapy or as monotherapy in PD-L1-high tumors), extensive-stage SCLC with chemotherapy, urothelial carcinoma and hepatocellular carcinoma combined with bevacizumab.

Triple-negative breast cancer with PD-L1-positive tumors and BRAF-mutated melanoma in combination regimens have also benefited.

Symptoms

Common side effects are fatigue, decreased appetite, nausea, cough, dyspnea and rash.
Immune-related events affect lungs, gastrointestinal tract, liver, endocrine glands, kidneys, skin and rarely the heart and nervous system.
Pneumonitis presents with new cough, dyspnea or oxygen desaturation; colitis with persistent diarrhea and abdominal pain.
Endocrinopathies include thyroid dysfunction, adrenal insufficiency, hypophysitis and type 1 diabetes.
Severe rare events include myocarditis, pancreatitis, hemophagocytic lymphohistiocytosis and severe cutaneous adverse reactions.

Risk Factors

Pre-existing autoimmune disease, prior thoracic radiation and interstitial lung disease are key risks.
Combination with bevacizumab raises bleeding and hypertension risk; with chemotherapy increases hematologic toxicity.
Chronic hepatitis B/C must be evaluated and managed before therapy.
Older age, frailty and multiple comorbidities affect tolerability.
Concomitant immunosuppressants may reduce efficacy and modify toxicity patterns.

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Worsening shortness of breath, persistent cough, fever or chest pain may indicate pneumonitis or infection.
  • Severe diarrhea, blood in stool, abdominal cramping or significant weight loss should be reported promptly.
  • Jaundice, dark urine, severe fatigue or right upper quadrant pain warrant urgent liver workup.
  • Severe headache, vision changes, hypotension, polyuria, polydipsia or unexplained collapse require emergent assessment.
  • Skin blistering, mucosal involvement, palpitations, neurological deficits or muscle weakness need immediate evaluation.

Treatment Methods

01
Grade 1 toxicities are managed with symptomatic care while continuing therapy under careful surveillance.
02
Grade 2 events usually require atezolizumab interruption and oral prednisone 0.5-1 mg/kg/day with gradual taper.
03
Grade 3-4 events lead to permanent discontinuation, intravenous methylprednisolone 1-2 mg/kg/day and second-line immunosuppression in steroid-refractory cases.
04
Endocrine toxicities require lifelong hormone replacement; treatment can typically continue once stable.
05
Multidisciplinary follow-up with oncology, pulmonology, hepatology, endocrinology and dermatology and patient education on early reporting underpin safe long-term care.

Which Department to Visit?

You can visit our Onkoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Onkoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.